Compare DHIL & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DHIL | AURA |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.8M | 419.5M |
| IPO Year | 1996 | 2021 |
| Metric | DHIL | AURA |
|---|---|---|
| Price | $174.99 | $8.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 15.8K | ★ 284.3K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 14.37 | N/A |
| EPS | ★ 17.91 | N/A |
| Revenue | ★ $145,201,729.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.77 | ★ N/A |
| Revenue Growth | ★ 6.69 | N/A |
| 52 Week Low | $114.11 | $4.73 |
| 52 Week High | $175.00 | $7.68 |
| Indicator | DHIL | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 70.47 | 71.58 |
| Support Level | $171.71 | $6.00 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.60 | 0.44 |
| MACD | 0.25 | 0.03 |
| Stochastic Oscillator | 99.72 | 90.77 |
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.